VERX Stock Recent News

Vertex Pharmaceuticals is a rare-disease drugmaker with over $10 billion in annual sales. The company's lead drug is the only available treatment for cystic fibrosis, a life-threatening progressive disease.

Product revenues increased by 6% to $2.65 billion, in line with market expectations. Management raised full-year product revenue guidance by $100 million.

Thursday, Vertex Pharmaceuticals Incorporated VTRX reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion.

Vertex Pharmaceuticals has consistently outperformed the S&P 500 and iShares Biotechnology ETF, reflecting its robust growth and market position. VRTX's diversified pipeline includes cystic fibrosis treatment, Vanzacaftor Triple, and the non-opioid pain management drug Suzetrigine, both with PDUFA dates expected in January 2025. Positioning the company for substantial future growth. The potential approvals of Vanza Triple will reinforce the Company's leadership in CF, while Suzetrigine's and the NOPAIN Act in 2025 will facilitate its entry into the lucrative pain management market.

There's a simple explanation for Vertex's glaring Q2 loss. The company raised its full-year product revenue guidance.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2024, and raised its full year product revenue guidance to $10.65 to $10.85 billion. “Vertex delivered another strong quarter of revenue growth coupled with outstanding execution across the business, and we are increasing our full year product revenue guidance,” said Reshma Kewalramani, M.D., Chief Executive Officer, and President of Ver.

Google Cloud will use Mistral AI's Codestral artificial intelligence model for Google's Vertex AI service, Google Cloud said on Wednesday.

HOUSTON--(BUSINESS WIRE)--Vertex Energy, Inc. (NASDAQ:VTNR) ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, today provided an update to its financial and operational outlook for the second quarter of 2024. Highlights include: Expected reductions in direct operating expense of 7% and capital expenditures of 29%, compared to previous guidance midpoints; Anticipated conventional throughput of 68,000 barrels per day (bpd), within guidance rang.

CRISPR Therapeutics and Vertex Pharmaceuticals are partners in one particular program, and they recently won approval for the gene-editing treatment Casgevy. Beyond Casgevy, Vertex has a billion-dollar portfolio of products; Casgevy marks CRISPR Therapeutics' first product approval.

KING OF PRUSSIA, Pa., July 11, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day.